Histopathologic Effects of Onabotulinum Toxin A Treatment in Pediatric Submandibular Glands.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 27879418.
- Also identified by DOI 10.1177/0194599816679940.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Onabotulinum toxin A (OBTXA) is an effective treatment for drooling. Our objective was to determine if there are histologic changes in the submandibular glands (SMGs) after repetitive OBTXA injections. The study included blinded histologic analysis and comparison of SMGs with ≥4 OBTXA injections versus controls who never received OBTXA. The number of acinar cells were counted, and the morphology of the cells was evaluated within each histologic sample of the SMGs. Thirty-one glands were analyzed (14 control, 17 cases). No physical differences were observed between the 2 acinar cell groups. There was no significant difference in the number acinar cells per surface area in the control group as compared with the OBTXA group (1.29 ± 0.13 vs 1.17 ± 0.11 cells/μm<sup>2</sup>, respectively). To conclude, no significant histologic findings were established in this first human study on SMGs post-OBTXA treatment.
Medical subject headings
- Acetylcholine Release Inhibitors
- Botulinum Toxins, Type A
- Sialorrhea
- Submandibular Gland